EFFECT OF RISEDRONATE AND STRONTIUM THERAPY ON BONE MINERAL DENSITY IN POSTMENOPAUSAL OSTEOPOROSIS

Clinical studies show that treatment with strontium ranelate which is comparatively a new oral agent leads to relatively larger increases in (Bone Mineral Density) BMD compared with alternative agents such as biphosphanates. The present study was designed to compare the effect of treatment with Risedronate and Strontium ranelate on clinical and radiological parameters, DEXA scans and various biochemical values. In this randomized controlled trial study, 190 patients were divided into two groups. The risedronate group (148 patients) received risedronate 35 mg weekly. Strontium group (42 patients) received strontium-ranelate 2 gm/day. The primary end point was the percentage of change at the end of one year over baseline in BMD at lumbar spine (L1 to L4) and femoral neck on both sides taken as mean. Secondary end points included clinical and radiological improvement with bone turn over markers. The mean difference in lumbar spine BMD at baseline and after one year of treatment with risedronate was 0.121 with a standard deviation change of 0.079. While in patients on strontium ranelate was 0.145 with a standard deviation change of 0.074. On applying the paired t-test to the pre and post-treatment BMD at hip and spine there was a significant improvement in both the treatment groups at spine (t= -10.997) (p< 0.05) and at hip (t= -7.60) (p< 0.05).There was a significant improvement in BMD at lumbar spine and total BMD at hip after one year treatment with risedronate and strontium ranelate. There was no significant difference between the two groups.